Anteris Technologies Global Corp. (AVR) Market Cap
Anteris Technologies Global Corp. has a market capitalization of $223.3M.
Financials based on reported quarter end 2025-12-31
Price: $6.07
▲ 0.11 (1.85%)
Market Cap: 223.31M
NASDAQ · time unavailable
CEO: Wayne Geoffrey Paterson
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2024-12-13
Website: https://anteristech.com
Anteris Technologies Global Corp. (AVR) - Company Information
Market Cap: 223.31M · Sector: Healthcare
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Analyst Sentiment
Based on 4 ratings
Analyst 1Y Forecast: $15.00
Average target (based on 1 sources)
Consensus Price Target
Low
$15
Median
$15
High
$15
Average
$15
Potential Upside: 147.1%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"AVR reported 2025 revenue of €31.0m and a net loss of €29.2m, with EPS of -€1.24. Net margin was strongly negative, reflecting profitability pressure that also shows up in cash generation: free cash flow was -€18.0m (operating cash flow -€18.3m) in the most recent cash flow period provided (ending 2025-09-30). Capital expenditure was relatively modest at €0.25m, but does not offset the cash burn. Balance sheet metrics are also stretched. Equity is slightly negative at -€0.25m, while total liabilities (€23.25m) slightly exceed total assets (€23.00m). Net debt is reported as -€10.29m, suggesting net cash positioning on the net-debt line, though the continued operating cash outflow is the key near-term risk. Valuation/market data provided includes a consensus price target of €15, but no valuation multiples (P/E, FCF yield, ROE) or market cap. From a shareholder-return perspective, market performance has been positive with a 1-year gain of 12.4% and a stronger 6-month move of 24.8%. With dividends paid at €0 and buybacks not provided, total shareholder returns appear driven mainly by capital appreciation rather than cash returns."
Revenue Growth
Revenue is provided at €31.0m for 2025, but no prior-year revenue figure is included to assess YoY growth or stability. Performance data shows price strength, yet underlying top-line growth cannot be quantified from the dataset.
Profitability
Profitability is materially negative: net income of -€29.2m and EPS of -€1.24 imply a strongly negative net margin. This signals significant earnings weakness and limited efficiency/return on capital in the period.
Cash Flow Quality
Cash generation remains weak: operating cash flow of -€18.3m and free cash flow of -€18.0m. Capex of €0.25m is modest, but does not prevent sustained cash outflow. No dividends were paid.
Leverage & Balance Sheet
Total equity is slightly negative (-€0.25m) with liabilities marginally above assets, indicating limited balance-sheet buffer. Net debt is shown as -€10.29m (net cash on that line), but continued operating losses increase resilience risk.
Shareholder Returns
Total shareholder value creation appears driven mainly by capital appreciation: +12.4% over 1 year and +24.8% over 6 months. Dividends are €0 and buybacks are not provided, so shareholder returns are not supported by cash distributions in the data.
Analyst Sentiment & Valuation
A consensus target of €15 is provided, but valuation multiples (P/E, FCF yield) and market cap are missing, limiting valuation-based scoring. The absence of FCF makes typical valuation assessment less informative, especially given negative earnings.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.